drugset / Trial / NCT01632527

Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD)

NCT01632527

Phase 1/2 Completed 15 enrolled StemCells, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this Phase I/II study is to investigate the safety and preliminary efficacy of unilateral subretinal transplantation of HuCNS-SC cells in subjects with geographic atrophy secondary to age-related macular degeneration.

Timeline

Start
2012-06
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Allogeneic Stem Cells Cell therapy 200000 cells Other
Subject Allogeneic Stem Cells Cell therapy 1e+06 cells Other